See more : STEP Energy Services Ltd. (SNVVF) Income Statement Analysis – Financial Results
Complete financial analysis of Caribou Biosciences, Inc. (CRBU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Caribou Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ANGLE plc (ANPCF) Income Statement Analysis – Financial Results
- Zhejiang Golden Eagle Co.,Ltd. (600232.SS) Income Statement Analysis – Financial Results
- G. G. Dandekar Machine Works Limited (GGDANDE.BO) Income Statement Analysis – Financial Results
- V2Y Corporation Ltd. (V2Y.SI) Income Statement Analysis – Financial Results
- Dr. Martens plc (DRMTY) Income Statement Analysis – Financial Results
Caribou Biosciences, Inc. (CRBU)
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 34.48M | 13.85M | 9.60M | 12.36M | 5.79M |
| Cost of Revenue | 112.08M | 3.64M | 984.00K | 34.43M | 23.64M |
| Gross Profit | -77.60M | 10.21M | 8.61M | -22.06M | -17.85M |
| Gross Profit Ratio | -225.07% | 73.71% | 89.75% | -178.50% | -308.34% |
| Research & Development | 112.08M | 82.23M | 52.26M | 34.43M | 23.64M |
| General & Administrative | 38.46M | 38.02M | 24.32M | 14.06M | 16.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 38.02M | 24.32M | 14.06M | 16.46M |
| Other Expenses | 0.00 | 7.18M | -1.35M | 514.00K | 0.00 |
| Operating Expenses | 150.54M | 120.25M | 76.58M | 48.49M | 40.09M |
| Cost & Expenses | 150.54M | 120.25M | 76.58M | 48.49M | 40.09M |
| Interest Income | 10.70M | 4.60M | 148.00K | 236.00K | 1.05M |
| Interest Expense | 0.00 | 0.00 | 8.00K | 20.00K | 4.00K |
| Depreciation & Amortization | 3.53M | 3.64M | 984.00K | 900.00K | 751.00K |
| EBITDA | -112.53M | -104.78M | -66.00M | -35.21M | -30.21M |
| EBITDA Ratio | -326.40% | -767.21% | -710.34% | -278.89% | -561.63% |
| Operating Income | -116.06M | -106.40M | -66.98M | -36.12M | -34.31M |
| Operating Income Ratio | -336.63% | -768.17% | -697.84% | -292.24% | -592.69% |
| Total Other Income/Expenses | 14.18M | 7.05M | 377.00K | -3.00K | 3.34M |
| Income Before Tax | -101.88M | -99.35M | -66.60M | -36.13M | -30.97M |
| Income Before Tax Ratio | -295.49% | -717.28% | -693.92% | -292.27% | -535.04% |
| Income Tax Expense | 193.00K | 70.00K | 321.00K | -1.82M | -7.54M |
| Net Income | -102.07M | -99.42M | -66.92M | -34.31M | -23.43M |
| Net Income Ratio | -296.05% | -717.79% | -697.26% | -277.55% | -404.82% |
| EPS | -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| EPS Diluted | -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| Weighted Avg Shares Out | 73.81M | 60.80M | 60.26M | 59.97M | 59.97M |
| Weighted Avg Shares Out (Dil) | 73.81M | 60.80M | 60.26M | 59.97M | 59.97M |
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing
Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
2 Magnificent Growth Stocks to Buy On the Dip
Source: https://incomestatements.info
Category: Stock Reports